Consistent with RMC-6236 sensitivity and KRAS dependency in human cancer cells in vitro (Fig. 1D; Supplementary Fig. S1F), RMC-6236 monotherapy drove durable antitumor activity and frequent regressions in KRASG12X xenograft models across all indications tested (Fig. 3A–G; Supplementary Table S4). Here, KRAS is linked to cancer.